Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19 : A systematic review with meta-analysis
| Errataetall: |
CommentOn: J Infect. 2023 Jan;86(1):e15-e17. - PMID 36031156 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:87 |
|---|---|
| Enthalten in: |
The Journal of infection - 87(2023), 1 vom: 01. Juli, Seite 82-84 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Ming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 21.02.2024 published: Print-Electronic CommentOn: J Infect. 2023 Jan;86(1):e15-e17. - PMID 36031156 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2023.04.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356498972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356498972 | ||
| 003 | DE-627 | ||
| 005 | 20240222091252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2023.04.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM356498972 | ||
| 035 | |a (NLM)37146726 | ||
| 035 | |a (PII)S0163-4453(23)00256-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Ming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Casirivimab-imdevimab treatment is associated with reduced rates of mortality and hospitalization in patients with COVID-19 |b A systematic review with meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Infect. 2023 Jan;86(1):e15-e17. - PMID 36031156 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a casirivimab and imdevimab drug combination |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Ao, Guangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Xiaodan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 87(2023), 1 vom: 01. Juli, Seite 82-84 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:87 |g year:2023 |g number:1 |g day:01 |g month:07 |g pages:82-84 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2023.04.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 87 |j 2023 |e 1 |b 01 |c 07 |h 82-84 | ||